Table 3.
Cox univariate and multivariate analysis for primary outcome
| Variables | Unadjusted p value |
Unadjusted HR (95% CI) | Model 1 | Model 2 | ||
|---|---|---|---|---|---|---|
| Adjusted p value |
HR (95% CI) | Adjusted p value |
HR (95% CI) | |||
| Age (years) | < 0.001 | 1.06 (1.04–1.08) | < 0.001 | 1.05 (1.02–1.07) | < 0.001 | 1.05 (1.03–1.08) |
| Women | 0.041 | 0.71 (0.51–0.98) | 0.012 | 0.64 (0.45–0.91) | 0.018 | 0.64 (0.45–0.93) |
| BMI(kg/m2) | 0.017 | 0.95 (0.92–0.99) | 0.275 | 0.98 (0.93–1.02) | 0.299 | 0.98 (0.93–1.02) |
| Systolic blood pressure | 0.395 | 1.00 (0.99–1.01) | ||||
| Heart rate | 0.275 | 0.99 (0.98–1.01) | ||||
| Dyslipidemia | 0.505 | 0.88 (0.61–1.28) | ||||
| Diabetes mellitus | 0.317 | 0.83 (0.58–1.20) | ||||
| Hyperuricemia | 0.381 | 1.21 (0.79–1.85) | ||||
| Atrial fibrillation | 0.101 | 1.33 (0.95–1.86) | ||||
| Coronary artery disease | 0.327 | 1.22 (0.82–1.83) | ||||
| COPD | 0.192 | 1.46 (0.83–2.60) | ||||
| Malignant tumor | 0.593 | 1.17 (0.66–2.07) | ||||
| Albumin | < 0.001 | 0.42 (0.30–0.59) | < 0.001 | 0.49 (0.34–0.71) | 0.001 | 0.51 (0.34–0.77) |
| Hemoglobin (g/dL) | < 0.001 | 0.87 (0.80–0.94) | 0.760 | 0.98 (0.90–1.08) | 0.852 | 0.99 (0.90–1.09) |
| eGFR (ml/min/1.73m2) | < 0.001 | 0.98 (0.97–0.99) | 0.027 | 0.98 (0.97–1.00) | 0.011 | 0.99 (0.98–1.00) |
| BNP (pg/ml) | 0.724 | 1.00 (1.00–1.00) | 0.882 | 1.00 (1.00–1.00) | ||
| ACEi/ARB | 0.516 | 0.89(0.63–1.26) | ||||
| Beta blocker | 0.642 | 0.92 (0.66–1.29) | ||||
| MRA | 0.209 | 0.81 (0.58–1.13) | ||||
| Loop diuretics | 0.042 | 1.64 (1.02–2.63) | 0.097 | 1.52 (0.93–2.49) | ||
| SGLT2i | 0.120 | 0.33 (0.08–1.33) | ||||
| Statins | 0.468 | 0.87 (0.59–1.27) | ||||
ACEi angiotensin-converting enzyme inhibitor, ARB angiotensin receptor blocker, BMI body mass index, BNP brain natriuretic peptide, CI confidence interval, COPD chronic obstructive pulmonary disease, eGFR estimated glomerular filtration rate, HR hazard ratio, MRA mineralocorticoid receptor antagonist, SGLT2i sodium glucose cotransporter 2 inhibitor